BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

11:00 AM
 | 
Aug 16, 2017
 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD); neurology

Mouse studies suggest electromagnetized nanoparticle-mediated in situ reprogramming of somatic cells into dopaminergic neurons could help treat PD. The reprogramming therapy involves lentiviral vectors encoding the dopaminergic neuron transcription factors ASCL1, LMX1A, NURR1 and PITX3 and gold nanoparticles coated with an integrin-interacting peptide to promote interaction...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >